Diabetic care presents a complex challenge, requiring diverse treatment options to improve patient outcomes effectively.
Adalvo's diabetes portfolio offers advanced therapies designed to address the underlying conditions of the disease. From small molecule inhibitors to peptide-based treatments, Adalvo offers a range of therapeutic options to make diabetic care manageable.
Adalvo's diabetes portfolio encompasses 9 INNs targeting type 2 diabetes, contributing to the market value of $85Bn with a 3Y CAGR of 30% in 2023, according to IQVIA.
At Adalvo, there are no half-measures - we are always on target. When your mission is to surpass your competitors, you need a dedicated team driving your vision forward.
Partner with us now!